Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | PPARD | Q03181 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32679459 | 0.81 | LMNA (0.59) | LMNACYP2C19CYP3A4CYP2C9TP53 | |
| SCHEMBL8403692 | 0.76 | CYP2C19 (0.40) | LMNACYP2C19CYP3A4CYP2C9TP53 | |
| SCHEMBL7894086 | 0.73 | — | — | |
| SCHEMBL10758272 | 0.73 | — | — | |
| SCHEMBL11237463 | 0.72 | CYP2C19 (0.39) | LMNACYP2C19CYP3A4CYP2C9TP53 | |
| SCHEMBL3244386 | 0.71 | LMNA (0.56) | LMNACYP2C19TDP1TSHRTHRB | |
| SCHEMBL27615314 | 0.71 | — | — | |
| SCHEMBL8069890 | 0.70 | — | — | |
| Ammonia Solution, Strong SCHEMBL10858881 | 0.70 | TSHR (0.40) | TP53TDP1GAAPPARDTSHR | |
| SCHEMBL10859409 | 0.70 | TSHR (0.40) | TP53TDP1GAAPPARDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4277467-A | ANTHELMINTICS, LARVICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1981-07-07 | — | — | US | claimed |
| US-8188043-B2 | Nicotine in therapeutic angiogenesis and vasculogenesis | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JR. UNIVERSITY (US) | 2012-05-29 | — | — | US | disclosed |
| US-7598275-B2 | Nicotine in therapeutic angiogenesis and vasculogenesis | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2009-10-06 | — | — | US | disclosed |
| US-20060182731-A1 | Nicotine in therapeutic angiogenesis and vasculogenesis | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2006-08-17 | — | — | US | disclosed |
| US-20060167028-A1 | Nicotine in therapeutic angiogenesis and vasculogenesis | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JR. UNIVERSITY | 2006-07-27 | — | — | US | disclosed |
| US-7078529-B2 | N-[1-(bi)cycloaliphatic-1H-imidazol-4-yl]-(bi)cycloaliphatic acetamides; central nervous system disorders; enzyme inhibitors of cyclin-dependent kinase-2 and -5, and glycogen synthase kinase-3 | PFIZER INC. (US) | 2006-07-18 | — | — | US | disclosed |
| US-20060149066-A1 | Imidazole derivatives | PFIZER INC | 2006-07-06 | — | — | US | disclosed |
| EP-1256578-B1 | Thiazole derivatives and their use as cdk inhibitors | PFIZER PROD INC (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20050209297-A1 | Pyrazole derivatives | PFIZER INC | 2005-09-22 | — | — | US | disclosed |
| US-20040192746-A1 | Thiazole derivatives | PFIZER INC | 2004-09-30 | — | — | US | disclosed |
| US-20020119963-A1 | Imidazole derivatives | PFIZER PRODUCTS INC. | 2002-08-29 | — | — | US | disclosed |
| US-20020111342-A1 | Methods for the inhibition of egg production in trematodes | THE INSTITUTE FOR ONEWORLD HEALTH | 2002-08-15 | — | — | US | disclosed |
| US-20020103185-A1 | Pyrazole derivatives | PFIZER PRODUCTS INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2002018346-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-03-07 | — | — | WO | disclosed |
| WO-2002010141-A1 | IMIDAZOLE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2002-02-07 | — | — | WO | disclosed |
| EP-0354761-B1 | Veterinary compositions for use against endoparasites, and their preparation | CHINOIN GYOGYSZER ES VEGYESZET (HU) | 1993-10-27 | — | — | EP | disclosed |
| US-5006545-A | Veterinary compositions against endoparasites containing cypermethrin and albendazole | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) | 1991-04-09 | — | — | US | disclosed |
| EP-0354761-A2 | Veterinary compositions for use against endoparasites, and their preparation | CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) | 1990-02-14 | — | — | EP | disclosed |
| US-4277467-A | ANTHELMINTICS, LARVICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1981-07-07 | — | — | US | disclosed |
| US-4022757-A | Dicarbamic acid diesters containing phosphorus | BAYER AKTIENGESELLSCHAFT (DT) | 1977-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209297-A1 | Pyrazole derivatives | CDK1, CDK3, CDK5 | LMNA 3466/4885CYP2C19 2689/4885CYP3A4 1927/4885 |
| US-20020103185-A1 | Pyrazole derivatives | CDK1, CDK5, CDK3 | LMNA 3606/4885CYP2C19 3279/4885CYP3A4 2118/4885 |
| US-20060149066-A1 | Imidazole derivatives | CDK1, CDK3, CKMT1A; CKMT1B | LMNA 3429/4885CYP2C19 3298/4885CYP3A4 2670/4885 |
| US-20060167028-A1 | Nicotine in therapeutic angiogenesis and vasculogenesis | TEK, FLT4, FLT1 | LMNA 4724/4885CYP2C19 3642/4885CYP3A4 3566/4885 |
| US-20040192746-A1 | Thiazole derivatives | CDK1, CDKL1, CDK5 | LMNA 3553/4885CYP2C19 3547/4885CYP3A4 2261/4885 |
| US-20020119963-A1 | Imidazole derivatives | CDK1, CDK3, CDK2 | LMNA 3317/4885CYP2C19 3299/4885CYP3A4 2331/4885 |
| US-20060182731-A1 | Nicotine in therapeutic angiogenesis and vasculogenesis | TEK, FLT4, FLT1 | LMNA 4724/4885CYP2C19 3642/4885CYP3A4 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.